https://eureka.patsnap.com/resources/blog/rd-blog/cell-free-expression-of-membrane-proteins-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Biotechnology & Synthetic Biology
Cell-Free Expression of Membrane Proteins: Patent Landscape

A patent landscape of cell-free expression of membrane proteins: 170 records from 2015–2026, filing trends, IPC composition, leading assignees and where claim space remains open.

170
Published Records
65%
Top-5 Share of All Records
0%
Filing Growth 2021→2024
WO
Leading Jurisdiction

Filing growth = 2021 (2 records) → 2024 (2); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 170 records in scope (CR5), not the ranked leaders only.

Check your own idea
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview

What this landscape covers

This landscape tracks 170 patent records published between 2015 and 2026 that combine cell-free protein synthesis or in vitro translation methods with membrane or transmembrane protein targets, using liposomes, nanodiscs, detergents or reconstituted membranes as the expression environment. The scope is narrow by design: it isolates the intersection of cell-free biology and membrane biochemistry rather than either field alone, so a general cell-free expression patent that never touches membrane proteins falls outside it, and a membrane protein patent that relies on cellular expression does too.

Coverage runs through a data cut-off of 2026-08-31, and because publication typically lags filing by roughly 18 months, the most recent one to two years understate real filing activity. Records are drawn from national and PCT filings, and the assignee ranking reflects 170 families across 89 ranked companies and institutions — the full set the data endpoint returns, not a top-50 or top-100 cut.

Filing activity and technology composition, 2015–2026
  1. 1CUREVAC SE42
  2. 2PROTEGENE21
  3. 3SAGAMI CHEM RES CENT21
  4. 4THE BRIGHAM & WOMEN S HOSPITAL INC14
  5. 5UTKU NALAN13
  6. 6M PHASYS10
  7. 7AGENCY FOR SCI TECH & RES10
  8. 8THE SCRIPPS RES INST10
  9. 9KATO8
  10. 10SEKINE SHINGO8
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Cell Free Expression of Membrane Proteins Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
The Data

Filing trends and technology composition

Two views of the same 170-record dataset: how filing activity has moved year over year, and which IPC subclasses carry the claim language.

A peak in 2017, then a flat plateau

Filings peaked at 10 in 2017 and have since settled into a low, flat pattern — 2021 and 2024 both recorded 2 filings, a 0% change over that three-year span. Treat the final one to two years on the chart as incomplete rather than as evidence of decline, since publication lag has not yet caught up with recent filing activity.

A peak in 2017, then a flat plateau0358101020172018201920202021202220232024202502026Most recent year is partial — publication lag means later filings are not yet visible.

Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.

Concentrated in genetic engineering and protein chemistry

C12N (microorganisms and genetic engineering) appears on 55.3% of the 170 records and C07K (peptides and proteins) on 44.1%, reflecting that most claims center on the expression system and the protein construct itself. A61K (medicinal preparations) reaches 41.8%, showing a strong therapeutic-development orientation, while C08G (condensation polymers), at 4.7%, marks the thinnest-claimed branch — a synthetic-membrane-material angle that few filers have committed to.

Concentrated in genetic engineering and protein chemistryC12N · Microorganisms & genetic engin…9455.3%C07K · Peptides & proteins7544.1%A61K · Medicinal preparations7141.8%C12P · Fermentation & enzymatic synth…3621.2%G01N · Material analysis & testing3621.2%A61P · Therapeutic activity of compou…3118.2%C12Q · Measuring & testing involving …1710.0%C08G · Condensation polymers84.7%Other3218.8%

Shares are the percentage of the 170 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Cell Free Expression of Membrane Proteins Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Cell Free Expression of Membrane Proteins Patent Landscape with Eureka

This page is one run against one query. Ask Eureka your own question about cell free expression of membrane proteins patent landscape and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Most-cited records and a representative filing

Representative Filing
US20030124614A12003-07-03

US20030124614A1 — T-cell membrane protein (TIRC7) and derived antibodies

BRIGHAMS AND WOMENS HOSPITAL INC.

The filing describes a T-cell immune response cDNA 7 (TIRC7) encoding a novel T-cell transmembrane protein, along with peptides, polypeptides and antibodies derived from it. Claimed elements include peptides and antibodies capable of inhibiting T-cell stimulation through the TIRC7 membrane protein, vectors carrying the relevant polynucleotides, host cells transformed with those vectors, and pharmaceutical and diagnostic compositions built around them.Filed by Brigham and Women's Hospital, this 2003 filing predates the cell-free expression methods now common in the field but still anchors claim territory around the TIRC7 membrane protein target and its antibody derivatives.

US20030124614A1 — patent drawing 1US20030124614A1 — patent drawing 2
View full record
Highest-cited records in this dataset
#Publication no.Patent titleCitations
1WO2013120629A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal …308
2WO2019157529A1Methods characterizing multiple analytes from individual cells or cell populations282
3WO2013120628A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal …236
4US20150057340A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal …184
5WO2013120497A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal …166
6WO2013120499A1Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal…137
7WO1999011782A1T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof55
8WO2008106660A2Isolated phospholipid-protein particles50
9US20170056529A1Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal …43
10US10166283B2Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal …39

Citation counts reflect an older cohort of records and should be read as a signal of influence within this corpus, not as a measure of current commercial relevance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Cell Free Expression of Membrane Proteins Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for a filing decision

Four read-outs from the same dataset, each pointed at a different practical question.

Concentration
65.3%
of 170 records held by the top 5 assignees

A small group holds most of the claim space

The leading assignee alone accounts for 42 of the 170 records in scope, and the top five combined reach 65.3% of all filings. That level of concentration means new entrants are more likely to be filing around a small number of dominant claim holders than competing against a diffuse field.

Top 10 combined reach 92.4% of all 170 records.
Filing momentum
0%
change, 2021 to 2024

Activity has plateaued since the 2017 peak

Filings peaked at 10 in 2017 and have not returned to that level since; 2021 and 2024 both sit at 2 filings apiece. This reads as a mature, narrow niche rather than a growth area, though the most recent one to two years are still filling in due to publication lag.

Peak year: 2017 at 10 filings.
Claim geography
55.3%
of records carry a C12N classification

Expression-system claims dominate over material claims

C12N (microorganisms and genetic engineering) and C07K (peptides and proteins) together anchor the bulk of claim language, while C08G (condensation polymers), at just 4.7% of records, marks a comparatively open branch on the materials side of membrane reconstitution.

IPC shares sum above 100% because records carry multiple classes.
Jurisdiction mix
40
PCT filings via WIPO, the largest single office

Filing strategy leans international before national

WIPO (PCT) filings lead at 40, ahead of Europe at 34 and the United States at 26, suggesting many applicants in this space are securing broad international priority before narrowing to specific national phases.

Canada (14) and Australia (13) follow as secondary destinations.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell free expression of membrane proteins patent landscape, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Derived observations on the same dataset. Derived from a Patsnap search on Cell Free Expression of Membrane Proteins Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The dataset points to a concentrated, plateaued field with a narrow set of dominant claim holders. The next steps depend on whether the goal is freedom-to-operate, licensing, or identifying open claim territory.

Map claims against the leading assignees

With 65.3% of records held by five entities, a freedom-to-operate review should start by pulling the granted claims of those five before evaluating the long tail of single- or few-filing entrants.

Explore assignee claims in Eureka

Test the under-claimed branches

C08G-classified records sit at only 4.7% of the dataset, well below C12N or C07K. Anyone with a materials-science angle on membrane reconstitution should check whether that gap reflects unmet technical difficulty or genuine open space.

Run a white-space search in Eureka

Watch for the publication-lag catch-up

Filing counts for 2025 and 2026 will rise as pending applications publish. Re-checking the trend in six to twelve months will show whether the 2021–2024 plateau is holding or whether recent activity has picked up.

Track filing trends in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Cell Free Expression of Membrane Proteins Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Cell Free Expression of Membrane Proteins Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Cell Free Expression of Membrane Proteins Patent Landscape in depth with Eureka

Go past this page: query the whole cell free expression of membrane proteins patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.